GNFT - GENFIT EV/EBITDA Multiple

Genfit S.A. (GNFT) aims for leadership in primary biliary cholangitis therapy with its drug Iqirvo, which is reflected in the asset value chart where the metric stands at 0.00. The business relies on creating a closed-loop treatment cycle by linking NIS4 tests with therapy. Additionally, Genfit S.A. (GNFT) is implementing methods to combat fibrosis, utilizing nuclear receptors for the therapy of metabolic disorders.

The EV/EBITDA multiple compares the total enterprise value, including debt, with operating profit before taxes and interest. This metric allows an investor to assess the real value of an asset by excluding the impact of debt load and tax regimes. When analyzing the current EV/EBITDA value of a company, one must consider the risk of overvaluation during shifts in market cycles. For Genfit S.A. (GNFT), this is critical when financing costly filtration systems and transitioning laboratories to green energy.